Xenon Pharmaceuticals Inc. (XENE) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for standing by. My name is Rebecca and I'll be your conference operator today. At this time, I would like to welcome everyone to the first quarter 2026 Xenon Pharmaceuticals Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, Simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press star one again. Thank you. I will now turn the call over to Colleen Alabisco, Senior Vice President of Corporate Affairs at Xenon. Please go ahead. Good afternoon. Thank you for joining us on our call and webcast to discuss Xenon's first quarter 2026 financial and operating results. Joining me today are Ian Mortimer, President and Chief Executive Officer, Dr. Chris Kenney, Chief Medical Officer, Darren Klein, Chief Commercial Officer, and Tucker Kelly, Chief Financial Officer. After completing our prepared remarks today, we will open the call up for your questions. Please be advised that during this call, we will make a number of statements that are forward-looking, including statements regarding the timing of and potential results from clinical trials, the potential efficacy, safety profile, future development plans in current and anticipated indications, addressable market regulatory success, and commercial potential in our partners' product candidates. the strength of our clinical trial designs, our ability to successfully develop and achieve milestones in our clinical development programs, including the anticipated filing of INDs and NDAs, the timing and results of those filings and our interactions with regulators, our ability to successfully ...